These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16575253)

  • 1. Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.
    Fernandez M; Yu T; Bjornson E; Luu H; Spotts G
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):165-71. PubMed ID: 16575253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion.
    DiMichele DM; Lasak ME; Miller CH
    Am J Hematol; 1996 Feb; 51(2):99-103. PubMed ID: 8579073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM).
    Parti R; Schoppmann A; Lee H; Yang L
    Haemophilia; 2005 Sep; 11(5):492-6. PubMed ID: 16128893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
    Pollmann H; Klamroth R; Vidovic N; Kriukov AY; Epstein J; Abraham I; Spotts G; Oldenburg J
    Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII.
    Takedani H
    Haemophilia; 2010 Sep; 16(5):740-6. PubMed ID: 20398072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD; Collins PW; Hay CR; Shapiro AD; Gruppo RA; Berntorp E; Bray GL; Tonetta SA; Schroth PC; Retzios AD; Rogy SS; Sensel MG; Ewenstein BM;
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
    Chen R; Gultyaev D; Lister J; Han R; Hu N; Malacan J; Solms A; Vashi P; O'Hara J; Hu S
    BMC Med Res Methodol; 2022 Aug; 22(1):215. PubMed ID: 35931967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
    J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of using recombinant factor VIIa in continuous infusion.
    Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
    Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
    Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A.
    Revel-Vilk S; Blanchette VS; Schmugge M; Clark DS; Lillicrap D; Rand ML
    Haemophilia; 2010 Jan; 16(1):72-9. PubMed ID: 19765092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion.
    Pesquera-Lepatan LM; Hernandez FG; Lim RD; Chua MN
    Haemophilia; 2004 Nov; 10(6):684-8. PubMed ID: 15569162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.